Excedrin sampling
This article was originally published in The Tan Sheet
Executive Summary
Novartis is linking its Excedrin to the equity of "Go" and its message of "The Pain Stops. You Don't." in its most recent advertising and marketing campaign for the headache reliever, the company states. In addition to launching new print and TV advertising spots, the firm has initiated a sampling program that "engages our target audience at lifestyle-appropriate venues and locations," Novartis states. The firm is targeting consumers that "meet our demographic of active lifestyles" at "on the go" locations venues including cruise ships, health clubs and coffee shops as well as commuter and college sampling. Novartis acquired Excedrin as part of its purchase of Bristol-Myers Squibb's Canadian Consumer Medicines business in September 2005 (1"The Tan Sheet" Sept. 5, 2005, In Brief)...
You may also be interested in...
Bristol/Novartis deal
Bristol-Myers Squibb has completed the sale of its U.S. and Canadian Consumer Medicines business to Novartis AG, the firm announces Aug. 31. The transfer of the rights to Bristol's OTC brands in Latin America, Europe, the Middle East and Africa should be completed by the end of the year, Bristol says. Novartis adds the Excedrin analgesic line, Bufferin aspirin, No-Doz caffeine pills and others to its current U.S. OTC line-up of brands, which include the Theraflu cough/cold line and Maalox antacids. The sale was announced July 14 (1"The Tan Sheet," July 18, 2005, p. 3)...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.